The Current Ratio as of September 2024 (TTM) for Galectin Therapeutics Inc. (GALT) is 1.87

According to Galectin Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.87. This represents a change of -3.07% compared to the average of 1.93 of the last 4 quarters.

Galectin Therapeutics Inc. (GALT) Historical Current Ratio (quarterly & annually)

How has GALT Current Ratio performed in the past?

The mean historical Current Ratio of Galectin Therapeutics Inc. over the last ten years is 7.70. The current 1.87 Current Ratio has changed 2.32% with respect to the historical average. Over the past ten years (40 quarters), GALT's Current Ratio was at its highest in in the September 2019 quarter at 41.51. The Current Ratio was at its lowest in in the December 2017 quarter at 1.29.

Galectin Therapeutics Inc. (GALT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Galectin Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Galectin Therapeutics Inc. (GALT) Average Current Ratio

How has GALT Current Ratio performed in the past?

The current Current Ratio of Galectin Therapeutics Inc. (GALT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Galectin Therapeutics Inc. (GALT) Current Ratio vs. Peers

How is GALT’s Current Ratio compared to its peers?

Galectin Therapeutics Inc.’s Current Ratio is less than Madrigal Pharmaceuticals, Inc. (8.72), less than Viking Therapeutics, Inc. (37.69), less than Sarepta Therapeutics, Inc. (3.90), less than Hepion Pharmaceuticals, Inc. (5.62), less than PTC Therapeutics, Inc. (2.23), less than Intercept Pharmaceuticals, Inc. (4.22), less than Terns Pharmaceuticals, Inc. (21.02), less than Akero Therapeutics, Inc. (24.89), less than Reata Pharmaceuticals, Inc. (3.21), less than DiaMedica Therapeutics Inc. (17.82), less than Milestone Pharmaceuticals Inc. (19.13), greater than Seres Therapeutics, Inc. (1.38), less than Inhibikase Therapeutics, Inc. (2.32), less than Oncolytics Biotech Inc. (4.99), less than 89bio, Inc. (13.92), less than Pliant Therapeutics, Inc. (14.47), less than Arcellx, Inc. (6.01), less than Stoke Therapeutics, Inc. (6.67),

Build a custom stock screener for Galectin Therapeutics Inc. (GALT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galectin Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Galectin Therapeutics Inc. (GALT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Galectin Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.